Journal Guide

Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.

All manuscripts will be peer reviewed according to the Journal's policy set out below and, if accepted for publication in the Journal, Authors will be notified of this decision and at the same time requested to pay an Article Processing Fee. Following payment of the Article Processing Fee, papers will be made open access. Letters to the editor which comment upon work previously published in either Gynecologic Oncology or Gynecologic Oncology Reports will be published free of charge.

This title is fully open access and therefore funded not through library subscription payments but through author fees. If you would like your article to be published open access, but you genuinely cannot afford these fees, then individual waiver requests are considered on a case-by-case basis and may be granted in cases of genuine need. Priority for this waiver programme will be given to applications by authors from countries eligible for the Research4Life programme (see http://www.research4life.org/institutions.html).

Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.

All manuscripts will be peer reviewed according to the Journal's policy set out below and, if accepted for publication in the Journal, Authors will be notified of this decision and at the same time requested to pay an Article Processing Fee. Following payment of the Article Processing Fee, papers will be made open access. Letters to the editor which comment upon work previously published in either Gynecologic Oncology or Gynecologic Oncology Reports will be published free of charge.

This title is fully open access and therefore funded not through library subscription payments but through author fees. If you would like your article to be published open access, but you genuinely cannot afford these fees, then individual waiver requests are considered on a case-by-case basis and may be granted in cases of genuine need. Priority for this waiver programme will be given to applications by authors from countries eligible for the Research4Life programme (see http://www.research4life.org/institutions.html).

Benefits to authors
We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our http://www.elsevier.com/wps/find/authorsview.authors/authorservicesauthor services.

Please see our http://www.elsevier.com/journals/gynecologic-oncology-reports/2352-5789/guide-for-authorsGuide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Effective with the 2011 volume, this journal will be published in an online-only format Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:

Hematology/Oncology Clinics of North America updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers8212;bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.
Hematology/Oncology Clinics of North America is published six times each year, in February, April, June, August, October, and December.

Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.

Immunotherapy offers the scientific community an interdisciplinary forum, providing them with the most recent advances of various aspects of immunotherapeutics to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research

Bioline International is a pioneer in the provision of open access to peer reviewed bioscience journals published in developing countries. These journals contain timely research on public health, international development, tropical medicine, food and nutritional security and biodiversity that would not otherwise be readily available to researchers in the developed world, or even within the country of publication. Bioline is not a publisher, but an aggregator that provides a free platform for journals who wish to participate in the global open access movement.

The Indian Journal of Surgical Oncology aims to encourage and promote clinical and research activities pertaining to Surgical Oncology. It also aims to bring in the concept of multidisciplinary team approach in management of various cancers.The Journal would publish original article, point of technique, review article, case report, letter to editor, profiles of eminent teachers, surgeons and instititions - a short (up to 500 words) of the Cancer Institutions, departments, and oncologist, who founded new departments.

Infectious Agents and Cancer is ready to receive manuscripts on all aspects of the pathogenic mechanisms of chronic infections and progression to oncogenesis.

Integrative Cancer Therapies (ICT) has been accepted by ISI. An impact factor will be released in the 2008 Journal Citation Reports®. Read the press release here.ICT is the first journal to spearhead and focus on a new and growing movement in cancer treatment. The journal emphasizes scientific understanding of alternative medicine and traditional medicine therapies, and their responsible integration with conventional health care. Integrative care includes therapeutic interventions in diet, lifestyle, exercise, stress care, and nutritional supplements, as well as experimental vaccines, chrono-chemotherapy, and other advanced treatments. Contributors are leading oncologists, researchers, nurses, and health-care professionals.The journal presents scientifically rigorous original research, case studies, current literature reviews, educational roundtables, and commentary on key topics such as: * Treatment strategies * Evaluations of current therapies * Models for integrating complementary and conventional treatment in clinical practice * Interventions from alternative and traditional medicine * Implementing quality-of-life assessment and counseling in the clinical setting * Cancer rehabilitation during and following cancer treatments * Potential interactions of cancer chemotherapy drugs with frequently used dietary supplements * Implementing integrative cancer care strategies into oncology practice * Relevant molecular mechanisms and biology behind integrative approaches * Impact of timing of chemotherapy administration on toxicity, response, and outcome .

International Journal of Breast Cancer is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies related to all aspects of breast cancer.

Aims and Scope TheInternational Journal of Cancer(official journal of the Union for International Cancer Control - UICC) appears 24 times per year.International Journal of Cancerinvites submissions under a broad scope of topics relevant to experimental and clinical cancer research and publishes original research articles. mini reviews. short reports. and letters to the editor. The article categories within the journal are: carcinogenesis. cancer cell biology. cancer genetics. infectious causes of cancer. tumor immunology. early detection and diagnosis. epidemiology. and cancer therapy. 2009 Impact Factor:4.

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.